tradingkey.logo

Rxsight Inc

RXST
View Detailed Chart

9.490USD

+0.530+5.92%
Close 09/18, 16:00ETQuotes delayed by 15 min
388.27MMarket Cap
LossP/E TTM

Rxsight Inc

9.490

+0.530+5.92%
Intraday
1m
30m
1h
D
W
M
D

Today

+5.92%

5 Days

+0.74%

1 Month

+11.78%

6 Months

-63.12%

Year to Date

-72.40%

1 Year

-82.48%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
84 / 207
Overall Ranking
213 / 4721
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 11 analysts
Hold
Current Rating
9.000
Target Price
+0.45%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Company’s RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 185.54% year-on-year.
Overvalued
The company’s latest PE is -11.94, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 40.83M shares, decreasing 8.24% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.27M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Company’s RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes.
Ticker SymbolRXST
CompanyRxsight Inc
CEODr. Ron M. Kurtz, M.D.
Websitehttps://www.rxsight.com/
KeyAI